ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Jordan, Fisher Win Brinker Awards; AFUD Forms 100th Us Too Prostate Cancer Support Group

October 30, 1992

Ultmann Appeals For Better Funding, Cancer Act Renewal

June 28, 1985

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

Evidence “Weak” Linking EMFs, cancer

June 25, 1999

In Brief: Ross Retires From Bristol-Myers, Forms Own Consulting Service; Obey Wins Key Post

April 1, 1994

Patient Satisfaction Was Crucial In ODAC Review Of Panretin

November 27, 1998